Treatment Patterns and Outcomes Study in Adults with Gastroenteropancreatic Neuroendocrine Tumors in the US

What this Trial Is About

Researchers are studying treatment approaches and clinical results among adults newly diagnosed with gastroenteropancreatic neuroendocrine tumors GEP-NET in the United States. This observational study uses open-source Longitudinal Prescription Claims and Patient Centric Medical Claims databases, combined with mortality data, to understand current treatment patterns and patient outcomes up to approximately 8 years after diagnosis. The study monitors various treatment regimens received by patients, including first-line and later-line therapies such as lutetium Lu 177 dotatate, capecitabine plus temozolomide CAPTEM, and cabozantinib. Participants are grouped based on the treatments they receive during different lines of therapy, and data on treatment duration, discontinuation, and switching between therapies is collected and analyzed. Participants medical and pharmacy claims data are reviewed to capture treatment patterns, therapy cycles, and timing of treatment changes. Key outcomes measured include the number of therapy lines, treatment regimens used, therapy discontinuation rates, and overall survival, with follow-up lasting up to around 8 years. Demographic and clinical characteristics are also recorded to provide a comprehensive view of treatment outcomes in this population.

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients